肿瘤微环境中非肿瘤细胞 PD-L1 的表达、调控及功能。

Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment.

机构信息

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China; Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing 211198, China.

出版信息

Drug Discov Today. 2024 Nov;29(11):104181. doi: 10.1016/j.drudis.2024.104181. Epub 2024 Sep 13.

DOI:10.1016/j.drudis.2024.104181

PMID:39278561

Abstract

Antiprogrammed death ligand 1 (PD-L1) therapy is a leading immunotherapy, but only some patients with solid cancers benefit. Overwhelming evidence has revealed that PD-L1 is expressed on various immune cells in the tumor microenvironment (TME), including macrophages, dendritic cells, and regulatory T cells, modulating tumor immunity and influencing tumor progression. PD-L1 can also be located on tumor cell membranes as well as in exosomes and cytoplasm. Accordingly, the dynamic expression and various forms of PD-L1 might explain the therapy's limited efficacy and resistance. Herein a systematic summary of the expression of PD-L1 on different immune cells and their regulatory mechanisms is provided to offer a solid foundation for future studies.

摘要

抗程序性死亡配体 1（PD-L1）治疗是一种领先的免疫疗法，但只有部分实体瘤患者从中受益。大量证据表明，PD-L1 在肿瘤微环境（TME）中的各种免疫细胞上表达，包括巨噬细胞、树突状细胞和调节性 T 细胞，调节肿瘤免疫并影响肿瘤进展。PD-L1 也可以位于肿瘤细胞膜上以及外泌体和细胞质中。因此，PD-L1 的动态表达和各种形式可能解释了该疗法的疗效有限和耐药性。本文系统总结了 PD-L1 在不同免疫细胞上的表达及其调控机制，为未来的研究提供了坚实的基础。